Hypersensitivity Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Type I Hypersensitivity

A
  • immediate hypersensitivity
  • mediated by IgE
  • commonly called allergies or atopic disorders
  • atopic individuals are 10-40% of the population are genetically susceptible and generally have higher levels of IgE and eosinophils
  • clinical manifestations (anaphylactic reactions) depend on the route of entry of the antigen (allergen) and the location of the responding cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Common source of allergens

A
  • inhaled- plant pollens, dander, mold spores, feces of dust mites
  • injected- insect venoms, vaccines
  • ingested materials- food, orally administered drugs
  • contacted materials- plant leaves, synthetic chemicals, metals
  • many are relatively low molecular weight, highly soluble and stable proteins that are carried on particles
  • contain peptides that can be presented by MHC II
  • effective at activating Th2- type cytokines especially IL-4, and stimulating an IgE response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Type I- Initial Sensitization

A
  • first exposure to allergen
  • antigen activation of TH2 cells and stimulation of IgE class switching in B cells
  • production of IgE
  • binding of IgE to FCERI on mast cells

other mechanisms of mast cell degranulation:

  • IgG cross-linking (IgE KO still develop antigen-induced degranulation)
  • C5a binds to complement receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Subsequent Exposures

A
  • allergen leads to mast cell degranulation
  • repeated exposure to allergen
  • activation of mast cell: release of mediators
  • vasoactive amines, lipid mediators- immediate hypersensitivty reaction (minutes after repeated exposure to allergen)- wheal (swelling from leakage-histamine effect) and flare (engorged with RBCs)
  • cytokines- late-phase reaction (2-4 hours after repeated exposure to allergen)- more widespread swelling inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Effects of Mast Cell Mediators

A
  • SRS-A (Slow releasing substance of anaphylaxis)- mixture of leukotrienes produced during response
  • Serotonin-affects vascular permeability
  • TNF stimulates expression of adhesion molecules on endothelial cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mast cell granules

A
  • enzymes like trypase, which contribute to tissue remodeling
  • toxic mediators like histamine, which increase vascular permeability and causes smooth muscle contractions
  • cytokines especially TNF alpha, which promotes inflammation and stimulates other cytokine production
  • chemokines like CCL3, which promotes influx of monocytes, macrophages and neutrophils
  • lipid activators like leukotrienes, which cause smooth muscle contraction, increase vascular permeability and are involved in smooth muscle contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mediators lead to influx of inflammatory cells

A
  • basophils- blood granulocytes with structural and functional properties similar to mast cells
  • eosinophils- bone-marrow derived granulocytes found in the inflammatory infiltrates of late phase reactions
  • reciprocally regulated- TGFB, IL-3 lead to increased basophils and decreased eosinophils, which are stimulated by IL-5 and GM-CSF
  • usually low levels unless activated and must be activated to express IgE FcR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Eosinophil and parasites

A
  • granulocyte response promotes expulsion of parasites by increased peristalsis and mucus
  • major basic protein- killing of parasites and host cells
  • enzymes like eosinophil peroxidase- tissue remodeling
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Response to Subcutaneous Allergen

A
  • like insect saliva
  • subcutaneous antigen, low dose
  • mast-cell activation
  • increased vascular permeability leads to localized swelling
  • localized swelling- urticaria (hives); deeper, more diffuse swelling is angiodema. Also eczema
  • mechanism in skin-testing for allergies (RAST assay for allergen-specific IgE)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Response to Inhaled Antigen

A
  • allergic rhinitis
  • first exposure to pollen
  • extraction of antigen
  • activation of antigen-specific T cells
  • protuction of IgE and binding to mast cells
  • peptides derived from pollen grains are presented by APCs to activate antigen-specific T cells, which secrete IL-4 resulting in isotype switch to IgE
  • if eyes affected- allergic conjunctivitis
  • inhaled antigen enter mucosa and activates mucosal mast cells locally
  • mast-cell activation causes blood-vessel permeability and activation of epithelium
  • eosinophils are recruited from blood and enter nasal passages with mucus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Allergic Asthma

A

Acute:
-mucosal mast cell captures antigen
-inflammatory mediators contact smooth muscle, increase mucus secretion from airway epithelium, and increase blood vessel permeability
Chronic:
-chronic response mediated by cytokines and eosinophil products
-TH2 cells that produce IL-13
-chronic asthma can occur in the absence of allergen-persons with chronic asthma are hyper-responsive to other irritants in the air such as cigarette smoke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cellular Infiltrate and Inflammation in Chronic Asthma Leads to Tissue Remodeling

A

-left occlusion of the airway of patient with chronic asthma by mucus plug (MP); right-inflammatory cell infilitrate and epithelium injury (L=lumen)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Reactions to Adsorbed Allergen-Food Allergies

A
  • ingestion of antigen activates mucosal mast cells
  • activated mast cells release histamine which acts on epithelium, blood vessels, and smooth muscle
  • antigen diffuses into blood vessels and is widely disseminated causing urticaria. Smooth muscle contraction induces vomiting and diarrhea. Fluid outfloq into gut lumen
  • common: milk,eggs, shellfish, fruit, nuts, legumes, grains, fish
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Responses to Systemic Allergen- Systemic Anaphylaxis

A
  • most severe form of a Type I reaction-antigens include drugs, serum, venom peanuts
  • antigen in bloodstream enters tissues and activates connective tissue mast cells throughout the body
  • mast cell degranulation and release of inflammatory mediators
  • heart and vascular system: increased capillary premeability and entry of fluid into tissues, swelling of tissues including tongue, loss of blood pressure, reduced oxygen to tissues, irregular heartbeat, Anaphylactic shock
  • respiratory- contraction of smooth muscle and constriction of throat and airways, difficulty in swallowing, difficulty in breathing, wheezing
  • GI tract- contraction of smooth muscle, stomach cramps, vomiting, fluid outflow into gut, diarrhea
  • treated with epinephrine (promotes the formation of tight junctions, relaxes bronchial smooth muscle, stimulates the heart)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Genetic predisposition

A

-genes that contribute include MHC and non-MHC (TcR, IL-4, IL-4 receptor, IgE receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hypersensitivity in Developed Countries

A
  • likely due to more vigilant hygiene and low parasite burden-IgE originally directed against parasites
  • Hygiene hypothesis- poorer hygiene results in exposure to Th-1 inducing infections which protect against allergy
  • but little allergy seen in worm infections that drive th-2?
  • counter regulation hypothesis- infections lead to production of IL-10 and TGF-B which downregulate both Th1 and Th2 responses, so less hypersensitivity
17
Q

Treatment for Type I

A
  • avoid the allergen
  • treat symptoms with antihistamines, corticosteroids, cromolyn sodium, montelukast (singulair), epinephrine, theophylline, albuterol
  • desensitization- controlled exposure to increased dose of antigen over time leads to IgA and IgG antibodies which block binding of allergens to IgE on mast cells
  • omalizumab- humanized anti-IgE
  • block effector mechanisms of allergic response- eg anti-cytokines
18
Q

Type II, III, and IV Hypersensitivity

A
  • may occur in response to foreign antigen
  • also when an individual’s immune system reacts against autologous (self) or modulated self-antigens -> autoimmunity
  • impacted by genetic susceptibility and environmental factors
19
Q

Type II Hypersensitivity

A
  • mediated by IgG
  • antibodies bind to a cell-associated antigen or cell surface receptor and fix complement
  • drug induced-drug binds to the surfaces of RBCs creating new epitopes. Lysis of RBCs- hemolytic anemia
  • lysis of platelets- thrombocytopenia
  • significant in ABO transfusion reactions
  • Grave’s disease, Hashimoto’s thyroiditis, and insulin resistant diabetes
20
Q

Type III Hypersensitivity

A
  • large quantities of soluble antigens and their antibodies develop and form large latticed immune complexes
  • isotype, valency, charge, and ability to fix complement determine IC pathogenicity
  • latticed immune complexes are pathologically capable of depositing systemically in any of a variety of tissue sites, creating downstream cellular damage with many different clinical presentations
  • IV- vasculitis, nephritis, arthritis; subcutaneous- arthus reaction; inhaled- Farmer’s lung
  • serum sickness, IgA nephrology, Lupus nephritis
  • post strep glomerulonephritis
21
Q

Arthus Reaction

A
  • locally injected antigen in immune individual with IgG antibody
  • local immune-complex formation activates complement. C5a binds to C5a receptor on mast cell
  • binding of immune complex to FcyRIII on mast cell induces
  • local inflammation, increased fluid and protein release, phagocytosis, and blood vessel occlusion
  • PMNs attracted to site produce lysosomal enzymes, causing tissue damage
  • Clinical- tetanus booster <5 years
22
Q

Serum Sickness

A
  • occurs after the development of antibody to antigen, about 7-10 days
  • may occur after large amounts of foreign protein such as antisera for snake bite, mouse antibodies as therapeutics, streptokinase
23
Q

Type IV Hypersensitivity

A
  • reactions are mediated by antigen specific effector TH1 cells, which initiate inflammatory reactions via the production of cytokines in response to antigen
  • occurs over 1-3 days
  • require 100-1000 times more antigen than an antibody-mediated hypersensitivity
  • reactions: delayed time hypersensitivity, contact hypersensitivity, celiac disease
24
Q

Delayed-type hypersensitivity

A
  • insect venom, mycobacterial proteins (tuberculin, lepromin)
  • localized swelling: erythema, induration, cellular infiltarte, dermatitis
  • antigen is introduced into subcutaneous tissue and processed by local APCs
  • a TH1 effector cell recognizes antigen and releases cytokines which act as vascular endothelium
  • recrutiment of T cells, phagocytes, fluid, and protein to site of antigen injection causes visible lesion
25
Q

Contact hypersensitivity

A
  • Haptens: Pentadecacatechol (poison ivy), DNFB
  • small metal ions: nickel, chromate
  • local epidermal reaction: erythema, cellular infilitrate, vesicles, intraepidermal abscesses
  • CD4+ T cells activate other immune cells white CD8+ T cells kill chemical-reacted cells that display foreign antigen
26
Q

Celiac Disease

A
  • Gluten-sensitive enteropathy
  • gliadin antigen
  • villous atrophy in small bowel, malabsorption
27
Q

Th1 T cells and IV hypersensitivity

A
  • antigen is processed by tissue macrophages and stimulates TH1 cels
  • chemokines- macrophage recruitment to site of antigen
  • IFN-gamma- activates macrophages, increasing release of inflammatory mediators
  • TNF-alpha and Lymphotoxin (TNF-beta): local tisue destruction, increased expression of adhesion molecules on local blood vessels
  • IL-3/GM-CSF- monocyte production by bone marrow stem cells
28
Q

Treatments of Type II, III, IV

A
  • avoid the antigen
  • reduce the impact of the immune response to the antigen with anti-inflammatories, steroids
  • reduce the immune response in general (steroids, cytoxan) or specifically (targeting pathogenic T and B cells)
  • induce regulation of the response- Treg (peptide vaccination)
  • block the effector mechanisms of allergic response- cytokines, co-stimulatory molecules